US 11,654,167 B2
Pharmaceutical composition based on bacteriophages against F. nucleatum; use in the treatment of diseases associated with this pathogen
Waldemar M. Bittner Ortega, Colina (CL); Pamela I. Machuca Valenzuela, Santiago (CL); Valeska S. Herrera Sanhueza, Santiago (CL); and Ignacio A. Fuentevilla Morgado, Santiago (CL)
Assigned to UNIVERSIDAD ANDRÉS BELLO, Santiago (CL)
Filed by UNIVERSIDAD ANDRÉS BELLO, Santiago (CL)
Filed on Apr. 21, 2021, as Appl. No. 17/236,645.
Application 17/236,645 is a division of application No. 16/348,655, granted, now 11,331,355, previously published as PCT/IB2016/056107, filed on Nov. 9, 2016.
Prior Publication US 2021/0299196 A1, Sep. 30, 2021
Int. Cl. A61K 35/76 (2015.01); A61P 31/04 (2006.01); A61K 9/00 (2006.01)
CPC A61K 35/76 (2013.01) [A61K 9/0053 (2013.01); A61P 31/04 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A method comprising administering to a subject a pharmaceutical composition comprising:
a) a therapeutically effective amount of bacteriophage FnnΦ107;
b) one or more pharmaceutically acceptable carrier and/or excipients;
wherein the bacteriophage FnnΦ107 is a lytic bacteriophage specific for Fusobacterium nucleatum.